Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial

Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial

Abstract Background Previous studies evaluating antiangiogenic agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma (HCC) have shown encouraging results. This study was conducted to investigate the efficacy and safety of donafenib combined with sintilimab (Don-Sin) for...

Full description

Saved in:

Bibliographic Details
Main Authors:	Xiaoyang Hong, Yongjian Guo, Wenbo Shi, Kangshun Zhu, Licong Liang, Liteng Lin, Ye Chen, Jingwen Zhou, Jingjun Huang, Jiabai Huang, Yaozhu Wu, Wensou Huang, Mingyue Cai
Format:	Article
Language:	English
Published:	BMC 2025-02-01
Series:	BMC Cancer
Subjects:	Hepatocellular carcinoma Tyrosine-kinase inhibitor Donafenib Immune-checkpoint inhibitor Programmed death 1 inhibitor Sintilimab
Online Access:	https://doi.org/10.1186/s12885-025-13605-2
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Did selective kinase inhibitors change the management of patients with radioiodine-refractory thyroid cancer?
by: Tommaso Porcelli, et al.
Published: (2025-02-01)

A Bibliometric Analysis of Medullary Thyroid Carcinoma From 2000 to 2022
by: TAN Meijuan, et al.
Published: (2024-07-01)

Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy
by: Anna De Lucia, et al.
Published: (2025-02-01)

Rechallenge therapy versus tyrosine kinase inhibitor (TKI) for advanced metastatic colorectal cancer: a retrospective study
by: Chenming Liu, et al.
Published: (2025-02-01)

Assessing hemorrhagic risks in combination therapy: implications of angiogenesis inhibitors and immune checkpoint inhibitors
by: Yuhui Yang, et al.
Published: (2025-02-01)

Bibliometric analysis of targeted immunotherapy for osteosarcoma-current knowledge, hotspots and future perspectives
by: Yunxiang Hu, et al.
Published: (2025-02-01)

Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study
by: Filip Van den Bosch, et al.
Published: (2025-02-01)

Full-length inhibitor protein is the most effective to perturb human dUTPase activity
by: Bianka Kőhegyi, et al.
Published: (2025-02-01)

Efficacy of high-dose steroids versus low-dose steroids in the treatment of immune checkpoint inhibitor-associated myocarditis: a case series and systematic review
by: Xiuyue Man, et al.
Published: (2025-02-01)

Exploratory study on the efficacy of topical pan-JAK inhibitor in ocular and skin GVHD in a sclerodermatous GVHD mouse model
by: Shinri Sato, et al.
Published: (2025-01-01)

Role of Janus Kinase inhibitors in the management of pulmonary involvement due to Long COVID-19 disease: A case control study
by: Pawan Kumar Singh, et al.
Published: (2023-07-01)

Prognostic value of the lactate dehydrogenase to albumin ratio in advanced non-small cell lung cancer patients treated with the first-line PD-1 checkpoint inhibitors combined with chemotherapy
by: Meifeng Luo, et al.
Published: (2025-02-01)

Case report: A severe myositis mimicking bulbar palsy after administration of immune checkpoint inhibitors
by: Philippe Rochigneux, et al.
Published: (2025-02-01)

The protective role of SGLT2 inhibitors on aortic aneurysm mediated by oxidative stress and inflammation in type 2 diabetes mellitus
by: Rujie Zheng, et al.
Published: (2025-02-01)

Interferon-free therapy of chronic hepatitis C: replacement of medications or new treatment paradigm?
by: S. N. Batskikh
Published: (2014-10-01)

Prognostic value of body adipose tissue parameters in cancer patients treated with immune checkpoint inhibitors
by: Yan Li, et al.
Published: (2025-02-01)

A case of immune checkpoint inhibitor-related conjunctivitis controlled by tacrolimus eye drops
by: Ayaka Kawaguchi, et al.
Published: (2025-03-01)

Six events that shaped antibody approvals in oncology
by: Suman Paul, et al.
Published: (2025-02-01)

Effects of perioperative treatment of resectable adenocarcinoma of esophagogastric junction by immunotherapy (Adebrelimab) combined with chemotherapy (XELOX): protocol for a single-center, open-labeled study (AEGIS trial, neoadjuvant immunochemotherapy)
by: Yingyi Li, et al.
Published: (2025-02-01)

Identifying factors for pembrolizumab eligibility in head and neck cancer
by: Satoru Miyamaru, et al.
Published: (2025-02-01)

The impact of PD-L1 polymorphisms on the efficacy of immune checkpoint inhibitors depends on the tumor proportion score: a retrospective study
by: Keiichiro Suminaga, et al.
Published: (2025-02-01)

Immunotherapy in metastatic renal cell carcinoma: Insights from a Dutch nationwide cohort
by: Hilin Yildirim, et al.
Published: (2025-02-01)

Prevalence and associated factors of metabolic syndrome among people living with HIV in a medical center of Northern Taiwan
by: Chien-An Tu, et al.
Published: (2025-02-01)

Targeted intervention of tumor microenvironment with HDAC inhibitors and their combination therapy strategies
by: Wanli Zhang, et al.
Published: (2025-02-01)

Gastroesophageal reflux disease, resistant to proton pump inhibitors
by: V. O. Kaybysheva, et al.
Published: (2011-06-01)

Pharmaceutical hemostasis at peptic ulcer bleeding: state-of-the-art and perspectives
by: A. A. Schegolev, et al.
Published: (2013-07-01)

<i>H. pylori</i> eradication therapy for patients receiving nonsteroid antiinflammatory drugs
by: V. T. Ivashkin, et al.
Published: (2012-11-01)

Editorial: Exploring small molecule inhibitors in cardiovascular and cerebrovascular diseases
by: Basveshwar Gawali, et al.
Published: (2025-02-01)

PARP Inhibitors in the Treatment of Ovarian Cancer
by: Andrzej Paweł Zuzak, et al.
Published: (2025-02-01)

Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer
by: Satoshi Endo, et al.
Published: (2025-01-01)

PI3Kδ inhibitor linperlisib combined with gemcitabine and oxaliplatin for relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm phase Ib/II trial
by: Peng Sun, et al.
Published: (2025-02-01)

Current Trends in Treatment for Acid-Dependent Diseases: Clinical Efficacy and Safety of Rabeprazole
by: O. D. Lopina, et al.
Published: (2021-12-01)

The SGLT-2 Inhibitors and their Role in the Treatment of Heart Failure - A Review of Literature
by: Silvia Ciraolo, et al.
Published: (2025-02-01)

Role of heat shock protein in radiation-induced effect and related potential clinical application
by: Ying Xu, et al.
Published: (2025-02-01)

Contemporary Approaches to the Treatment of Gastroesophageal Reflux Disease
by: Boris D. Starostin
Published: (2019-03-01)

Deprescribing and Optimal Selection of Proton Pump Inhibitors (Contributions of the 26th United Russian Gastroenterology Week)
by: V. T. Ivashkin, et al.
Published: (2020-12-01)

Angiotensin-Neprilysin Inhibitor Therapy: A Retrospective Chart Study
by: Roda Plakogiannis, et al.
Published: (2025-02-01)

Tyrosine Kinase-2, Angiopoietin-2, and Thrombomodulin Axes in the Late-Onset Fetal Growth Restriction: A Prospective Cohort Study
by: Esra Altan Erbilen, et al.
Published: (2024-12-01)

Do NSAID/COX-2 Inhibitors Increase Nonunion After Fracture Surgery? Dilemma and Consideration In Use
by: Azmi
Published: (2022-10-01)

Pharmacological inhibition of carbonic anhydrases with a positively charged pyridinium sulfonamide phenocopies the neuroprotective effects of Car9 genetic ablation in a murine setting of oxygen/glucose deprivation followed by re-oxygenation and is associated with improved neuronal function in ischemic rats
by: Sara Amiranda, et al.
Published: (2025-02-01)